MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, APTOF had -$2,611K decrease in cash & cash equivalents over the period. -$21,990K in free cash flow.

Cash Flow Overview

Change in Cash
-$2,611K
Free Cash flow
-$21,990K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from loan payable with ...
    • Accrued liabilities
    • Accounts payable
    • Others
Negative Cash Flow Breakdown
    • Other assets
    • Change in operating lease liabil...
    • Repayment of loan with related p...

Cash Flow
2025-12-31
Net loss
-25,468
Stock-based compensation
477
Change in fair value of warrants
0
Depreciation of property and equipment
22
Loss on disposal of property and equipment
0
Noncash operating lease expense
396
Interest on lease liabilities
34
Interest on loan payable to related party
843
Prepaid expenses
-44
Other assets
2,958
Change in operating lease liability
-462
Accounts payable
1,653
Accounts payable, related party
0
Accrued liabilities
3,429
Cash used in operating activities
-21,990
Proceeds from disposal of property and equipment
0
Purchase of property and equipment
0
Cash provided by investing activities
0
Proceeds from loan payable with related parties
18,650
Repayment of loan with related party
100
Issuance of common shares and warrants-November Two Thousand And Twenty Four Public Offering
0
Issuance of common shares-June2024Registered Direct Offering
0
Proceeds from warrant exercise-June Two Thousand And Twenty Four Pre Funded Warrant
0
Issuance of common shares and warrants-January Two Thousand And Twenty Four Public Offering
0
Issuance of common shares and warrants-Hanmi Private Placement
0
Issuance of common shares-Two Thousand Twenty Three Committed Equity Facility
0
Issuance of common shares-The2022Atm Offering
0
Issuance of common shares-The2025ATMOffering
828
Issuance of common shares-Employee Stock Purchase Plan
1
Cash provided by financing activities
19,379
Decrease in cash, cash equivalents, restricted cash and restricted cash equivalent
-2,611
Cash, cash equivalents, restricted cash and restricted cash equivalents, beginning of year
6,707
Cash, cash equivalents, restricted cash and restricted cash equivalents, end of the year
4,096
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from loanpayable with related...$18,650K Issuance of commonshares-The2025ATMOffering$828K Issuance of commonshares-Employee Stock Purchase...$1K Cash provided byfinancing activities$19,379K Canceled cashflow$100K Decrease in cash, cashequivalents, restricted cash...-$2,611K Canceled cashflow$19,379K Accrued liabilities$3,429K Accounts payable$1,653K Interest on loan payableto related party$843K Stock-based compensation$477K Noncash operating leaseexpense$396K Prepaid expenses-$44K Interest on leaseliabilities$34K Depreciation of property andequipment$22K Repayment of loan withrelated party$100K Cash used inoperating activities-$21,990K Canceled cashflow$6,898K Net loss-$25,468K Other assets$2,958K Change in operatinglease liability-$462K

Aptose Biosciences Inc. (APTOF)

Aptose Biosciences Inc. (APTOF)